Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 8 July 2027
- Last conf. stmt
- 24 June 2026
Celleron Therapeutics Limited
- Incorporated
- 24 June 2004 (22 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Nicholas Barrie La Thangue
- Owned by
- Accounts type
- Total exemption full
- Region
- South East
- Address
- Magdalen Centre Robert Robinson AvenueOxford Science ParkOxfordOX4 4GA
Charges
- Total
- 1
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 1
Officers 1 active
Officer details are public data from the Companies House register.
La Thangue, Nicholas Barrie, Prof
Director · Appointed 24 June 2004
British
Born November 1957
Officer history (13 former)
18 September 2024
21 February 2023
Resigned Kerr, David James, Prof as Director
21 February 2023
Resigned Taylor, Richard Kirby as Director
21 February 2023
Resigned Noble, James Julian as Director
22 December 2022
Resigned Mcdonald, Douglas Fraser as Secretary
22 December 2022
24 March 2022
Resigned Innes-Ker, Katherine, Dr as Director
23 November 2021
Resigned Chun, Ji Woong as Director
13 September 2021
Appointed Innes-Ker, Katherine, Dr as Director
13 September 2021
Appointed Taylor, Richard Kirby as Director
31 August 2021
Resigned Manion, Doug as Director
16 August 2021
22 October 2019
Appointed Noble, James Julian as Director
17 May 2017
Appointed Manion, Doug as Director
17 May 2017
Resigned Whittaker, Frederick John, Dr as Director
16 December 2016
Appointed Chun, Ji Woong as Director
23 September 2016
1 October 2012
Appointed Whittaker, Frederick John, Dr as Director
30 September 2011
Appointed Kerr, David James, Prof as Director
18 February 2011
Resigned Kerr, David James, Professor as Director
17 April 2009
Appointed Mcdonald, Douglas Fraser as Secretary
17 April 2009
9 March 2005
Appointed Kerr, David James, Professor as Director
9 March 2005
Resigned Williams, Robert John, Dr as Director
24 June 2004
Appointed La Thangue, Nicholas Barrie, Prof as Director
24 June 2004
Appointed Williams, Robert John, Dr as Director
24 June 2004
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 22 December 2022
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Limited By Shares
Reg. no. 14127227
Former controllers (1)
22 December 2022
Ceased Nicholas Barrie La Thangue — Owns 25–50% of shares
Group structure 3 companies
Ownership group derived from the Companies House PSC register
Argonaut Therapeutics Limited Owns 75–100% of shares
Celleron Therapeutics Limited This company Owns 75–100% of shares
Financials
Balance sheet as at 31 December 2025 · total exemption full accounts
- Cash
- £3,646
- Current Ratio
- 16.0x
Trend
Shareholder Funds
Balance sheet detail
| 2025 | 2024 | 2020 | 2019 | |
|---|---|---|---|---|
| Fixed Assets | £100 | £276,759 | £304,657 | |
| Current Assets | £494,939 | £489,756 | £3,872,012 | £5,329,813 |
| Debtors | £491,293 | £264,269 | £822,337 | £752,504 |
| Cash | £3,646 | £225,487 | £3,049,675 | £4,577,309 |
| Creditors (< 1 year) | £31,002 | £25,819 | £830,739 | £744,350 |
| Net Current Assets | £463,937 | £463,937 | £3,041,273 | £4,585,463 |
| Shareholder Funds | £464,037 | £464,037 | £3,318,032 | £4,890,120 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 8 July 2026 | Total exemption full accounts | 31 December 2025 | ||
| 26 June 2026 | Confirmation statement with no updates | 24 June 2026 | ||
| 23 September 2025 | Total exemption full accounts | 31 December 2024 | ||
| 26 June 2025 | Confirmation statement with no updates | 24 June 2025 | ||
| 31 December 2024 | Insolvency filing |
Some other companies at this address
Other companies in this industry
Altrincham
Manchester
Liverpool
Caerphilly
Oxford
By trade and location
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →